Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer

Lin, Qunying; Guo, Lei; Lin, Guo; Chen, Zhiwei; Chen, Tonghuan; Lin, Juan; Zhang, Bo; Gu, Xiaobin

doi:10.1016/j.canep.2015.05.010

Cited by 51 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, several clinical trials showed that the combination therapy with erlotinib plus bevacizumab resulted in significantly longer PFS than EGFR‐TKI therapy alone in EGFR ‐mutant NSCLC patients, including patients with pleural effusion . In addition, the previous study reported that the high levels of VEGF expression in NSCLC tissue were identified as an independent poor prognostic factor . Because VEGF levels in malignant pleural effusion caused by lung cancer were significantly higher than VEGF levels in benign exudative pleural effusion, EGFR ‐mutant NSCLC patients with pleural effusion may have had a worse survival rate, consistent with our study result.…”

Section: Discussionsupporting

confidence: 89%

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis

et al. 2019

View full text Add to dashboard Cite

Background In epidermal growth factor receptor ( EGFR )‐mutant non‐small cell lung cancer (NSCLC), brain metastasis is known as a poor prognosis factor. However, prognostic factors in the patients without brain metastasis remain unclear. In this study, we aimed to clarify the differences between metastatic site and prognosis in common EGFR ‐mutant NSCLC patients without brain metastasis. Methods Chemotherapy‐naïve, advanced EGFR ‐mutant NSCLC patients without brain metastasis diagnosed between January 2010 and March 2016 were enrolled. We evaluated prognosis according to the presence or absence of bone metastases, liver metastasis, and pleural effusion. Results A total of 50 EGFR ‐mutant NSCLC patients without brain metastasis were enrolled. The median progression‐free survival and overall survival were significantly shorter in patients with pleural effusion than in those patients without (progression‐free survival 7.0 months, 95% confidence interval [CI] 3.7–13.0 vs. 13.0 months, 95% CI 9.1–21.7, hazard ratio [HR] 2.29, 95% CI 1.11–4.73, P = 0.020; overall survival 19.5 months, 95% CI 5.7–28.8 vs. 55.3 months, 95% CI 24.0–not evaluable, HR 3.00, 95% CI 1.35–6.68, P = 0.005). Pleural effusion was an independent factor of poor prognosis for progression‐free survival (HR 3.44, 95% CI 1.50–7.88, P = 0.003) and overall survival (HR 2.34, 95% CI 1.00–5.44, P = 0.049). Conclusion Pleural effusion might be a poor prognosis factor for advanced EGFR ‐mutant NSCLC patients without brain metastasis treated with first‐generation EGFR‐tyrosine kinase inhibitors. Further precision medicine according to the metastatic site is required.

show abstract

Section: Discussionsupporting

confidence: 89%

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Consistent with previous studies, gelsolin and osteopontin exhibited higher expression in LAC tissues than adjacent normal tissues [17–19]. These proteins were elevated in blood and play important roles in tumor progression and metastasis [20, 21], but both were downregulated in LAC patient urine samples.…”

Section: Discussionsupporting

confidence: 89%

Identification of urine biomarkers associated with lung adenocarcinoma

Wang

Zhang

2017

Oncotarget

View full text Add to dashboard Cite

Lung adenocarcinoma (LAC) progression is accompanied by changes in protein levels that may be reflected in body fluids, such as urine. Urine collected from LAC patients (n=34) and healthy controls (n=36) was analyzed via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) combined with weak cationic exchange magnetic beads. The results revealed 76 urinary polypeptides significantly different between LAC patients and normal controls (P<0.05). Twenty-two of these peptides were up-regulated and 54 were down-regulated. Thirteen peptides had average peak intensities >600. Twelve of these 13 peptides were successfully identified using nano-liquid chromatography-tandem MS. Receiver operating characteristic analyses identified seven peptides with superior LAC diagnostic performances. Immunohistochemical staining in 20 paired LAC and adjacent normal tissues showed that IGKC, AAT, SH3BGRL3, osteopontin and gelsolin levels were higher in LAC tissues than in adjacent tissuesand were closely associated with LAC. Urinary peptides assessments may thus provide a novel, noninvasive, repeatable method for detecting and monitoring LAC. New, low-cost detection methods and bioinformatics tools are therefore urgently needed for the analysis of low abundance proteins and peptides in body fluids.

show abstract

“…OPN is one of the known factors that have been considered to be correlated with the progression and severity of certain cancer types, including lung, breast, colon and prostate (16)(17)(18)(19).…”

Section: Discussionmentioning

confidence: 99%

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro

Hao

Cui

et al. 2017

View full text Add to dashboard Cite

show abstract

Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer

Cited by 51 publications

References 23 publications

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis

Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis

Identification of urine biomarkers associated with lung adenocarcinoma

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro

Contact Info

Product

Resources

About